<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586543</url>
  </required_header>
  <id_info>
    <org_study_id>MAO201901</org_study_id>
    <secondary_id>2019-002685-12</secondary_id>
    <nct_id>NCT04586543</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma</brief_title>
  <official_title>A Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>László Mangel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>E-Group ICT Software Informatikai Zrt.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the effectiveness and safety of&#xD;
      selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy -&#xD;
      among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is one of the leading cause of cancer death among males worldwide. The&#xD;
      objective of this phase II, randomized, controlled, open label study is to evaluate the&#xD;
      effectiveness and safety of MAO-B (Monoamine oxidases-B) inhibitor selegiline plus docetaxel&#xD;
      therapy. Patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma are&#xD;
      randomly divided into two groups. One group (control arm) receives docetaxel (75 mg/m2 IV&#xD;
      every 3 weeks for maximum of 12 cycles). Another group (experimental arm) receives docetaxel&#xD;
      (75 mg/m2 IV every 3 weeks for maximum of 12 cycles) plus selegiline (daily 10 mg tablet).&#xD;
      Patients are followed up for 36 months or until the end of the trial, death or withdraw from&#xD;
      this study due to other reasons. The primary endpoint of this study is the proportion of&#xD;
      patients without progression at month 9. The secondary endpoint is proportion of patients&#xD;
      without progression at month 12/18, progression-free survival, overall survival, duration of&#xD;
      PSA response, radiological response rate, PSA response rate, health-related quality of life&#xD;
      and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients without progression at month 9</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients without progression at month 9. Progression can be identified by clinical symptoms, PSA levels, or radiographic imaging as follows, based on PCWG2 criteria:&#xD;
Progression based on clinical symptoms:&#xD;
Decline in ECOG performance status (≥ grade 3),&#xD;
Initiation of newly adjusted chronic opioid analgesic therapy, which may be,&#xD;
i.Use of oral opioid for at least 3 weeks ii.Use of parenteral opioid for at least 7 days c.Necessity to initiate alternative cytotoxic chemotherapy or other active systemic oncology treatment d.Immediate need for radiation or surgical intervention to treat tumor progression OR&#xD;
PSA progression: Date at which the PSA level is increased by at least 25% relative to nadir and at least 2 ng / mL absolute increase compared to the nadir. Values are confirmed 4-6 weeks later by a test.&#xD;
OR&#xD;
Radiological&#xD;
Progression by RECIST 1.1.&#xD;
Bone scan progression: A total of ≥ 2 new lesion compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients without progression at month 12</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients without progression at month 18</measure>
    <time_frame>21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (biochemical, clinical, radiological</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PSA response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Response Rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Response Rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Adenocarcinoma of the Prostate</condition>
  <arm_group>
    <arm_group_label>Selegiline+ Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selegiline and plus Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selegiline</intervention_name>
    <description>10 mg selegiline tablet per day</description>
    <arm_group_label>Selegiline+ Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_label>Selegiline+ Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older male patients,&#xD;
&#xD;
          2. Histologically or cytologically confirmed prostate adenocarcinoma&#xD;
&#xD;
          3. Radiologically confirmed metastatic disease,&#xD;
&#xD;
          4. Eligibility to receive oral therapy,&#xD;
&#xD;
          5. Suitable for docetaxel therapy,&#xD;
&#xD;
          6. Patients with castration-resistant prostate carcinoma who eligible to first-line&#xD;
             docetaxel therapy or patients with castration-resistant prostate cancer who progressed&#xD;
             after second-generation hormone therapy (abiraterone or enzalutamide) with&#xD;
             pre-chemotherapy indication and eligible to second-line docetaxel therapy&#xD;
&#xD;
          7. At least 4 weeks has elapsed between the last antiandrogenic therapy and the inclusion&#xD;
             (at least 6 weeks in case of bicalutamide),&#xD;
&#xD;
          8. Planned docetaxel treatment,&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status: ≤ 2,&#xD;
&#xD;
         10. Estimated life expectancy of more than 12 weeks,&#xD;
&#xD;
         11. Adequate analgesic therapy as required;&#xD;
&#xD;
         12. Patients must be able to follow the diet and medical instructions,&#xD;
&#xD;
         13. Use of effective contraception in men of childbearing age,&#xD;
&#xD;
         14. Provision of signed, written information consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. De novo metastatic patients who needs immediate docetaxel therapy;&#xD;
&#xD;
          2. Within 4 weeks prior to randomisation, the patient has received other study medication&#xD;
             or failed to recover from any adverse events caused from a previously administered&#xD;
             study drug&#xD;
&#xD;
          3. ≥ Grade 2 anticancer therapy-related toxicity (except alopecia),&#xD;
&#xD;
          4. Has had radiotherapy or immunotherapy within 4 weeks prior to treatment,&#xD;
&#xD;
          5. Has had a surgery within 4 weeks prior to treatment,&#xD;
&#xD;
          6. Known or suspected brain metastasis (stable patients with locally treated,&#xD;
             asymptomatic brain metastases are not excluded),&#xD;
&#xD;
          7. Inadequate laboratory function:&#xD;
&#xD;
               1. Absolute neutrophil count &lt;1.5 x 109 /L (1,500 per mm3),&#xD;
&#xD;
               2. Platelet count &lt; 100 x 109 /L (100 000 per mm3),&#xD;
&#xD;
               3. Hemoglobin ≤9.0 g/dL,&#xD;
&#xD;
               4. Serum bilirubin &gt; ULN,&#xD;
&#xD;
               5. AST or ALT&#xD;
&#xD;
             i.&gt;2.5 x ULN in patient without liver metastases, ii.&gt;5x ULN in patients with liver&#xD;
             metastases.&#xD;
&#xD;
          8. Cardiological status:&#xD;
&#xD;
               1. Uncontrolled hypertension (BP ≥ 150/95 with hypertension treatment)&#xD;
&#xD;
               2. Heart failure (NYHA III or higher),&#xD;
&#xD;
               3. Current or former diagnosis of cardiomyopathy,&#xD;
&#xD;
               4. LVEF ≤ 50%,&#xD;
&#xD;
               5. Atrial fibrillation with &gt;100bpm pulse,&#xD;
&#xD;
               6. Unstable ischemic heart disease (myocardial infarction within 6 months or angina&#xD;
                  that require more than one nitrate therapy each week).&#xD;
&#xD;
          9. Other uncontrolled or severe systemic disease, active infection, hepatitis B,&#xD;
             hepatitis C, HIV,&#xD;
&#xD;
         10. Uncontrolled seizure disorder,&#xD;
&#xD;
         11. Active gastric and duodenal ulcers,&#xD;
&#xD;
         12. Recurrent nausea and vomiting, chronic gastrointestinal disease or intestinal&#xD;
             resection that prevents proper absorption,&#xD;
&#xD;
         13. Severe psychiatric illness (including but not limited to manic psychiatric disorder,&#xD;
             schizophrenia, bipolar disorder, major depression requiring hospitalization) or social&#xD;
             disturbance that limits eligibility for examination,&#xD;
&#xD;
         14. History of other malignancy within the last 5 years (except properly treated basalioma&#xD;
             or squamous cell carcinoma of the skin and in situ carcinoma),&#xD;
&#xD;
         15. History of allergic reaction to phenelzine, selegiline or other monoamine oxidase&#xD;
             inhibitors (MAOIs) biological agents or similar chemical ingredients,&#xD;
&#xD;
         16. History of allergic reaction to docetaxel therapy or its ingredients,&#xD;
&#xD;
         17. Significant peripheral neuropathy (≥ Grade 2),&#xD;
&#xD;
         18. Selegiline is contra-indicated for concomitant use with:&#xD;
&#xD;
               1. Certain narcotic analgesics (eg. pethidine),&#xD;
&#xD;
               2. Drugs that enhance the sympathetic nervous system,&#xD;
&#xD;
               3. Other MAO inhibitors,&#xD;
&#xD;
               4. Drugs similar to MAO inhibitors,&#xD;
&#xD;
               5. Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine&#xD;
                  reuptake inhibitors (SNRIs),&#xD;
&#xD;
               6. Tricyclic antidepressants.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>László Mangel, Prof. MD</last_name>
    <phone>+36-72-536-480</phone>
    <email>mangel.laszlo@pte.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pécs, Clinical Centre, Department of Oncotherapy</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>László Mangel, Prof. MD</last_name>
      <phone>+36-72-536-480</phone>
      <email>mangel.laszlo@pte.hu</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pecs</investigator_affiliation>
    <investigator_full_name>László Mangel</investigator_full_name>
    <investigator_title>Prof MD</investigator_title>
  </responsible_party>
  <keyword>selegiline</keyword>
  <keyword>hormone-refractory prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Selegiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

